These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25432147)

  • 1. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
    Messmer MN; Netherby CS; Banik D; Abrams SI
    Cancer Immunol Immunother; 2015 Jan; 64(1):1-13. PubMed ID: 25432147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of metabolism-driven myeloid dysfunctions in cancer therapy.
    Strauss L; Guarneri V; Gennari A; Sica A
    Cell Mol Immunol; 2021 Apr; 18(4):829-841. PubMed ID: 33077904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
    Lu B; Yang M; Wang Q
    J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
    Poggi A; Musso A; Dapino I; Zocchi MR
    Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of immature myeloid cells in mechanisms of immune evasion in cancer.
    Kusmartsev S; Gabrilovich DI
    Cancer Immunol Immunother; 2006 Mar; 55(3):237-45. PubMed ID: 16047143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy.
    Lebegge E; Arnouk SM; Bardet PMR; Kiss M; Raes G; Van Ginderachter JA
    Front Immunol; 2020; 11():1395. PubMed ID: 32733461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.
    Daveri E; Vergani E; Shahaj E; Bergamaschi L; La Magra S; Dosi M; Castelli C; Rodolfo M; Rivoltini L; Vallacchi V; Huber V
    Front Immunol; 2020; 11():1214. PubMed ID: 32793185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.
    Bhatia A; Kumar Y
    Expert Rev Clin Immunol; 2014 Jan; 10(1):41-62. PubMed ID: 24325346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction.
    Alvarez R; Oliver L; Valdes A; Mesa C
    Semin Oncol; 2018 Jan; 45(1-2):84-94. PubMed ID: 30318088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
    Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
    J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
    Filipazzi P; Huber V; Rivoltini L
    Cancer Immunol Immunother; 2012 Feb; 61(2):255-263. PubMed ID: 22120756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of myeloid-derived suppressor cells.
    Condamine T; Mastio J; Gabrilovich DI
    J Leukoc Biol; 2015 Dec; 98(6):913-22. PubMed ID: 26337512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune escape mechanisms as a guide for cancer immunotherapy.
    Beatty GL; Gladney WL
    Clin Cancer Res; 2015 Feb; 21(4):687-92. PubMed ID: 25501578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The growing diversity and spectrum of action of myeloid-derived suppressor cells.
    Mantovani A
    Eur J Immunol; 2010 Dec; 40(12):3317-20. PubMed ID: 21110315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The path to reactivation of antitumor immunity and checkpoint immunotherapy.
    Kim HJ; Cantor H
    Cancer Immunol Res; 2014 Oct; 2(10):926-36. PubMed ID: 25281320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tricks tumors use to escape from immune control.
    Whiteside TL
    Oral Oncol; 2009 Oct; 45(10):e119-23. PubMed ID: 19467917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
    Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.